HOME ABOUT US PRINT PUBLICATIONS SUBSCRIPTIONS CONTACT US TELL FRIEND RSS

Welcome to FDAweb Pay Per View Search our 45,601 - story database FREE   Free Items  Warning Letters  FDA Notices  FDA Calendar    FDA Whistleblowers          << Prev  18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 Next >>   Guidance on Self-Selection Studies for Non-Rx Drugs [100 Words] [ Price : $7.95] Federal Register Notice: FDA releases a guidance on self-selection studies to support nonprescription drug product applications. 04/11/2013     Guidance on Device Product Codes [59 Words] [ Price : $7.95] Federal Register Notice: FDA releases a guidance, Medical Device Classification Product Codes. 04/11/2013     Sales Reps Rarely Offer Adverse Event Info [142 Words] [ Price : $7.95] Researchers say drug company sales representatives generally don’t provide sufficient adverse event information to prescribing doctors. 04/11/2013     Nonprescription Drug Self-Selection Study Guidance [160 Words] [ Price : $7.95] FDA issues a guidance on consumer self-selection studies for nonprescription drug products. 04/11/2013     Concerns Raised on Electronic Source Data Draft Guidance [349 Words] [ Price : $7.95] Several companies and organizations offer FDA suggestions for improving a draft guidance on electronic source data in clinical investigations. 04/11/2013     Journals Need Explicit Ghostwriting Policy: Study [159 Words] [ Price : $7.95] Researchers say too few biomedical journals have explicit policies about ghostwritten articles. 04/11/2013     FDA Selects Disease Areas for Drug Development Initiative [99 Words] [ Price : $7.95] Federal Register Notice: FDA selects 12 disease areas to address during its Patient-Focused Drug Development initiative. 04/11/2013     Praise, Questions for FDA’s Alzheimer’s Drug Guidance [345 Words] [ Price : $7.95] Several drug companies and advocacy organizations express support for FDA’s draft guidance on developing new drugs to treat early-stage Alzheimer’s disease. 04/10/2013     Merck Seeks Approval for Noxafil Tablet Formulation [91 Words] [ Price : $7.95] FDA accepts a Merck NDA for a tablet formulation of its antifungal agent Noxafil, which is currently approved as an oral suspension. 04/10/2013     Comments Sought on Info Collection on Tobacco Health Documents [91 Words] [ Price : $7.95] Federal Register Notice: FDA seeks comments on tobacco health document submission. 04/10/2013     << Prev  18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37  Next >>

FERDIC INCORPORATED - P.O. Box 28, Camp Hill, PA 17001 | Phone: (717)731-1426 fax:(717)731-1427 Email: info@fdaweb.com